Journal Information
Vol. 61. Issue 10.
Pages 610-616 (October 2025)
Share
Download PDF
More article options
Vol. 61. Issue 10.
Pages 610-616 (October 2025)
Review Article
Residual Excessive Daytime Sleepiness in Obstructive Sleep Apnoea and New Pharmacological Possibilities for Treatment
Visits
151
Grace Osculloa,b, Amina Bekkia, Jose Daniel Gómez-Olivasa, Miguel Ángel Martínez-Garcíaa,b,
a Servicio de Neumología, Hospital Universitario y Politécnico La Fe, Valencia, Spain
b CIBER de Enfermedades Respiratorias, Madrid, Spain
Podcast
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Tables (3)
Table 1. Differential diagnosis of residual excessive daytime sleepiness in obstructive sleep apnoea.
Tables
Table 2. General characteristics of the main wakefulness-promoting agents.
Tables
Table 3. Future challenges in the treatment of wakefulness-promoting agents.
Tables
Show moreShow less
Additional material (2)
Abstract

Excessive daytime sleepiness is one of the most important symptoms in obstructive sleep apnoea and it is often used to decide whether the latter should be diagnosed as a syndrome or considered a priority in diagnosis and treatment, and whether the treatment is effective. Beyond this, one concept of enormous clinical significance has emerged: “residual excessive daytime sleepiness”, defined as excessive daytime sleepiness in the context of a diagnosed obstructive sleep apnea that is treatable with continuous positive airway pressure (CPAP) or alternatives to it; it appears as a consequence of poor adaptation to, or refusal of treatment, or even sometimes in situations of good tolerance. Given the direct relationship between excessive daytime sleepiness (usually defined by an Epworth Sleepiness Scale [ESS] value of more than 10 points) and cardiovascular, neurocognitive and quality-of-life disorders, attempts have been made for years to alleviate it with drugs (modafinil, armodafinil, sodium oxybate or amphetamines), to little effect and with a large number of adverse effects. However, unlike their predecessors, two products that have recently appeared on the market – solriamfetol and pitolisant – have achieved clinically significant reductions without any major adverse effects, in most cases. In fact, a Task Force from the European Respiratory Society has even proposed an algorithm for residual excessive daytime sleepiness and its pharmacological treatment in the context of obstructive sleep apnoea. The present review aims to define the importance of excessive daytime sleepiness, especially residual excessive daytime sleepiness in patients with obstructive sleep apnoea, as well as the old and new pharmacological alternatives that have appeared.

Keywords:
Sleep apnea
Pitolisant
Solriamfetol
Sleep-disordered breathing

Article

These are the options to access the full texts of the publication Archivos de Bronconeumología
Member
If you are a member of SEPAR:
  • Go to >>>SEPAR<<< website and sign in.
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Email
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?